<DOC>
	<DOCNO>NCT00203801</DOCNO>
	<brief_summary>The purpose study study efficacy sulfadoxine-pyrimethamine compare efficacy new combination antimalarial therapy , either sulphadoxine-pyrimethamine plus artesunate artemether-lumefantrine .</brief_summary>
	<brief_title>Combination Antimalarials Uncomplicated Malaria</brief_title>
	<detailed_description>The resistance Plasmodium falciparum anti-malarial drug serious impediment control malaria . In South East African Combination Anti-malarial Therapy ( SEACAT ) evaluation , comprehensive evaluation phase introduction combination anti-malarials ( CAT ) Mozambique , Swaziland South Africa . In order facilitate formulation effective regional drug policy provide database decision-making implementation combination therapy , essential vivo response CAT three country investigate . An SP therapeutic efficacy study conduct accord modify WHO protocol guide selection CAT . After CAT introduce vivo CAT efficacy study conduct evaluate efficacy artesunate plus SP ( artemether-lumefantrine KwaZulu Natal Limpopo ) . In area low intensity malaria transmission CAT vivo study result compare across site find baseline monotherapy , site .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<criteria>Male female , old 12 month . Weight &gt; 10 kg . Diagnoses uncomplicated acute P. falciparum malaria parasitaemia 250 000 asexual parasite/mcl blood axillary temperature great equal 37.50C history fever Documented inform consent Lives close enough health centre reliable follow Has receive antimalarial treatment past 7 day . Severely ill ( base WHO Criteria severe malaria ) patient consider , opinion investigator designee , moderately severe malaria ( e.g . prostrate , repeat vomiting , dehydrate ) . Has receive cotrimoxazole chloramphenicol past 7 day . History G6PD deficiency ( contraindication artemetherlumefantrine ) . Is pregnant breastfeeding . Has history allergy study drug ( include sulphonamides e.g . cotrimoxazole , artemisinin derivative e.g . artemetherlumefantrine ) .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Gametocyte</keyword>
	<keyword>Molecular marker</keyword>
	<keyword>Sulfadoxine-pyrimethamine</keyword>
	<keyword>Artesunate</keyword>
	<keyword>Artemisinin</keyword>
</DOC>